Radiographic assessment of sarcopenia in the trauma setting: a systematic review.

BACKGROUND: Compared with similarly injured patients of a younger age, elderly patients have worse outcomes from acute injury. One factor adversely affecting outcomes is sarcopenia, which has been assessed in healthy elderly populations through established clinical and radiological criteria. However, in the acute care setting, no such criteria have been established. Sarcopenia has been opportunistically assessed via radiographic means but there is as of yet no gold standard. The purpose of this review is to summarize the radiological methods used to diagnose sarcopenia in the acute care setting, and suggest ways in which these methods may lead to a consensus definition of sarcopenia and its relationship to patient outcomes.
METHODS: A systematic survey of medical databases was conducted, with 902 unique publications identified. After screening and application of inclusion and exclusion criteria, data regarding study population, outcome, imaging modality, and criteria for assessment of sarcopenia were extracted from 20 studies. Quality was assessed with the Newcastle-Ottawa Scale.
RESULTS: CT was the imaging modality for 18 of the studies, with total psoas muscle cross-sectional area at the level of L3 and L4 being the dominant method for assessing sarcopenia. Adjustment for body morphology most commonly used patient height or L4 vertebral body area. The majority of articles found radiographically assessed sarcopenia to be significantly correlated to outcomes such as mortality, length of hospital stay, morbidity, and in-hospital complications.
CONCLUSIONS: Establishing a consistent definition would strengthen its applicability and generalizability to admission and discharge planning. LEVEL OF EVIDENCE: Systematic review, level III. © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Background

Elderly patients suffering from a broad range of traumatic injuries have worse outcomes than younger patients with similar injury.1 2 One factor adversely affecting outcomes in ageing populations is sarcopenia.3 Sarcopenia is characterized by loss of skeletal muscle, decreased muscle strength and low physical performance.4 It has been demonstrated that the presence of sarcopenia is a marker for poor outcome in the elderly with a critical illness5 or traumatic injury.6 7 These patients therefore may require modification and personalization of care and interventions to counteract the increased likelihood of adverse health events.8 Consequently, identification, measurement, and stratification of sarcopenia in this population early in the course of clinical care can be beneficial in guiding clinical decision-making.8 Although it is acknowledged that sarcopenia plays a role in patient outcomes in the setting of trauma, there is no uniform, established method of measuring it, nor any consensus on practical application.

There are a number of existing sarcopenia assessment tools in the healthy elderly population. The European Working Group on Sarcopenia in Older People (EWGSOP) recently published a framework for diagnosing the elderly with sarcopenia.8 Their diagnostic algorithm in stepwise order includes a clinical questionnaire, muscle strength test, muscle quantity or quality test, and a physical performance test. The ESPEN Special Interest Group uses muscle mass and walking speed as the main criteria for a diagnosis of sarcopenia.9 Although such methods are available when assessing healthy elderly patients, many cannot be readily applied at the time of presentation in those with traumatic injury. This leaves muscle quantity or quality measurement through radiological imaging the only reliable assessment available in the acute setting.

Currently, there are several modalities to measure muscle quantity and quality. Appendicular skeletal muscle mass (ASMM) may be measured through dual-energy X-ray absorptiometry (DXA),10 whole-body skeletal muscle mass may be predicted by bioelectrical impedance analysis (BIA),11 12 and specific muscle cross-sectional area (CSA) or volume can be measured through CT or MRI.10 13 Of these assessments, only ASMM measured through DXA or BIA has established cut-off points for diagnosis of sarcopenia in the EWGSOP’s diagnostic algorithm.14 15 However, BIA is particularly sensitive to hydration status16 so will be potentially confounded when this is changing secondary to hemorrhage, resuscitation and fluid shifts between compartments. MRI and CT are considered to be the gold standard for non-invasive assessment of muscle quantity and mass,11 but there are a variety of stratification points, measurement locations, and methods employed to diagnose sarcopenia. In addition, the impact of demographic factors such as age, sex, body mass index, and ethnicity on specific muscle measurements has not been well explored. Given the wide use and availability of radiological measurement devices, establishment of a single criterion for measurement of sarcopenia in the acute setting could be greatly beneficial in bringing this information to bear on the clinical care of elderly patients. This review will therefore summarize the radiological methods that have been used to diagnose sarcopenia in the setting of trauma, and suggest ways in which these methods may lead to a consensus definition of sarcopenia and its role in patient outcomes.

Objectives

The objectives of this systematic review are: to summarize the current methods and outcomes associated with radiographically assessed sarcopenia in the setting of traumatic injury, to highlight areas of consensus and disagreement among researchers, and to propose directions for future research.

Methods

Research questions

This systematic review focuses on the radiographic evaluation of muscle mass as an indicator of potential pre-existing sarcopenia, in the setting of trauma, guided by the following research questions. First, what population are study subjects drawn from, with particular focus on inclusion criteria used. Second, what imaging modalities were used in the assessment of sarcopenia. Third, what were the criteria on which an assessment of sarcopenia was made and, finally, what was the reported relationship between sarcopenia and the outcomes of interest to investigators, specifically mortality, length of hospital stay, morbidity, in-hospital complications, and independence after discharge.

Search strategy

The following databases were searched for relevant studies: PROSPERO, MEDLINE, and Cochrane Central Register of Controlled Trials. Searches were conducted between January 17 and 30, 2019. The search strategy used keywords identified by the authors, informed by the results of a preliminary probing search, to capture published articles which addressed the concept of radiographically defined sarcopenia in the acute care setting. Search queries included combinations of the following sets of terms: ‘sarcopenia’, ‘iliopsoas’, ‘psoas’, ‘psoas major’, ‘trauma’, ‘acute care’, ‘imaging’, ‘measure’, and ‘radiographic’. Search results were limited to studies published in or translated to English on or after January 1, 1999. A total of 902 unique records were collected, after removal of duplicate articles. The flowchart of the article selection pathway is shown in figure 1.

Figure 1

Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram illustrating article selection. Source: Moher et al31

Inclusion criteria

Inclusion criteria were established prior to the literature search. Studies reporting the prevalence of radiographically defined sarcopenia and its association with outcomes in adult patients (>18 years of age) admitted after traumatic injury were sought. Studies were included if the radiographic studies used to assess sarcopenia were performed at admission or within the 72 hours after admission.

Exclusion criteria

Studies which did not specify the timing of the imaging studies relative to admission, or studies in which the patient population was not assessed in the acute care setting, were excluded. Studies published in languages other than English were also excluded, as were studies published prior to January 1, 1999.

Study selection

Duplicates were removed from the initial collection of records, after which investigators independently screened articles. The full texts of articles meeting inclusion criteria were independently reviewed for relevance to the research questions.

Data extraction

Data extraction was performed independently by two investigators (CEC, DMZ). Extracted data included study type, publication year, sample size, sex (%male), age, population, criteria for inclusion, timing of imaging, imaging modality, blinding of image assessor, muscles assessed, anatomic references used to assess muscles, muscle characteristics assessed, any adjustment for body morphology, criteria for sarcopenia, and relation of sarcopenia to outcome.

Quality assessment

The Newcastle-Ottawa Scale (NOS) is a tool for assessing the quality of non-randomized studies. For this review, the NOS permitted a consistent evaluation of each included study based on study group selection, comparability, and outcome.

Results

Measurement of the total CSA of the psoas via CT was the imaging modality of choice for the majority of the studies included in analysis. The L3 vertebral body was the most common anatomic landmark identified as a reference point, with patient height most commonly used for normalization of psoas CSA. With two exceptions, definitions of sarcopenia were made relative to the distribution of adjusted psoas CSA in the population studied, and the outcome most frequently explored by researchers was mortality.

Study quality

Each source included for analysis was evaluated for the selection of study groups, comparability of the groups, and assessment of outcome using the NOS. None of the studies specified whether patients in their study population had a history of sarcopenia, and there was variable comparability across studies regarding comparability of cohorts, but otherwise each study rated highly on the NOS (see online supplementary digital content 1).

Study population characteristics

A total of 18 studies were included in the analysis, of which 17 were retrospective and the remaining study was prospective. Sample size varied widely, with the greatest sample size having 23 622 patients and the smallest having 16. Average age, gender ratio, and country of origin are shown in table 1. Populations included in studies were, on average, 55% male, with a mean age of 69 years. The average minimum age for inclusion across all studies was 54 years. The majority of studies included for review drew from North American cohorts, with a handful of other nationalities represented, including Italian, Australian, and Japanese.

Table 1

Study population characteristics

First author	Year	Study design	Sample size	Gender (%male)	Age (mean)	Population	Criteria for inclusion
Akahoshi22	2016	Retrospective	84	56	47.2	Japanese	Age >20; not DOA; blunt force trauma
Chang21	2018	Retrospective	91	26	81.1	American	Age >50; proximal femur fracture undergoing surgical repair
Couch32	2018	Retrospective	225	55	76.9	Australian	Age >65; Injury Severity Score (ISS) >12
DeAndrade33	2018	Retrospective	778	71	63 and 42	American	Presented as a trauma alert at a single institution from 2012 to 2014
Deren25	2017	Retrospective	99	62	74.3	American	Age ≥60; Rhode Island Hospital Trauma Database; closed acetabular fracture
Ebbeling23	2014	Retrospective	180	57	74	American	Age >55 years; ISS>15; and ICU LOS>48 hours; captured in Pennsylvania Trauma Outcomes Study (PTOS)
Fairchild19	2015	Retrospective	252	49	76	American	Age >65; no TBI/SCI; admitted to level 1 trauma center in Milwaukee, WI, between January 2008 and April 2011
Hida17	2016	Retrospective; cross-sectional	216 (OVF); 1608 (NF)	0	79.9 (OVF); 69.1 (NF)	Japanese	Women ≥55 admitted to single hospital with osteoporotic vertebral fracture (OVF); (NF) consecutive female outpatients who underwent DXA during study period (June 2002 to January 2009)
Hu34	2018	Retrospective	108	73	67.4	American	Age ≥55; all patients admitted to the trauma service of a single university hospital (level 1 trauma center); TBI
Kaplan18	2017	Retrospective Cohort	450	60	Stratified by age, not specified	American	Age ≥65 years; admitted to the ICU of a single institution from January 2011 to May 2014 after traumatic injury
Leeper6	2016	Retrospective	23 622	61.70	Stratified by age, not specified	American	Age ≥18 or older; level 1 or level 2 trauma alert; availability of at least 6 months of follow-up data
Lisiecki35	2013	Retrospective	16	75	47.1	American	Age between 18 and 99 years old; mandible fracture; treated in initial hospital stay; GCS score of 14–15
Malekpour26	2017	Retrospective	1175	51	78.17	American	Age >65; blunt trauma; abdominal CT
Mccusker36	2018	Retrospective	325	64	76	American	Age ≥65 years; trauma patients admitted to level 1 trauma center
Mitchell37	2018	Retrospective	146	73	70.1	American	Age >60 with acetabular fractures treated at institution during a 12-year period
Oskutis38	2016	Retrospective	202	41	58.5	American	Age >40; postcrash admission to a trauma center; single injury or Maximum Abbreviated Injury Scale (MAIS) score ≥3
Shibahashi24	2017	Retrospective	74	72	74	Japanese	Age ≥60 years; TBI; admitted to the intensive care unit between September 2013 and September 2015
Touban20	2019	Retrospective	558	46	76.65	American	Age >65 years; evaluation with abdominal and/or pelvic CT; orthopedic injury

DOA, Dead On Arrival; DXA, dual-energy X-ray absorptiometry; GCS, Glasgow Coma Scale; ICU, intensive care unit; LOS, length of stay; NF, Non-fracture; SCI, Spinal Cord Injury; TBI, traumatic brain injury.

Imaging modalities

Imaging was undertaken in all studies at the time of admission, with a minority of studies specifying the window of time (eg, <1 hour after arrival). CT was the imaging modality for 17 of the studies included, with DXA used in one study. The blinding of the image assessors was specified in only five studies, of which blinding was present in three.

Of the 17 studies which used CT imaging modalities, the psoas was the dominant muscle group, assessed in 11 studies. Of those, two studies assessed additional muscles, such as paraspinal muscles (quadratus lumborum, erector spinae). Total skeletal muscle CSA at the level of the anatomic reference was used in four studies, and muscles of mastication (masseter, temporalis) in two studies. Finally, DXA imaging modalities assessed upper and lower extremity muscle mass.

Anatomic reference points

Anatomic reference points used for CT imaging modalities focused on the L3 and L4 vertebral level, as described in table 2. Nine studies assessed muscles via axial slices determined by the features of the L3 vertebrae, with three studies explicitly specifying the level (eg, caudal end), and four studies following similar methodology at the L4 vertebrae. Two studies assessed muscles at the level of an intervertebral disc; one at L3-L4 and one at L4-L5. Due to the nature of the DXA scan, no anatomic reference points were used for muscle assessment.

Table 2

Anatomic reference points for CT imaging modalities

Vertebral level	Further specification	Studies, n
L3 axial slice		9
	Not specified	6
	Superior aspect	2
	Inferior aspect	1
L3-L4 disc		1
	Superior aspect	1
L4		4
	Not specified	1
	Inferior aspect	3
L4-L5 disc		1
	Not specified	1
Other		2
	Superior orbital rim, external meatus, mandibular coronoid process	1
	2 cm below zygomatic arch	1

Assessment of sarcopenia

The assessment of sarcopenia in each study was predicated on characteristics of the muscles assessed, with or without adjustment for body morphology, as described in table 3. The majority of studies used skeletal muscle index (SMI) of the psoas, which normalizes the CSA of the muscles of interest against the height of the patient. Four studies assessed the CSA of the psoas without adjustment for body morphology, with one study assessing the CSA of the masseter. Other metrics included the psoas:lumbar vertebral index (computed as the ratio between the mean CSAs of the psoas muscles and the L4 vertebral body at the level of the L4 pedicles17 and muscle volume of the temporalis), used in one study each. ASMM-to-height ratio was used with DXA analysis.

Table 3

Assessment of sarcopenia

Muscle characteristics assessed	Morphology adjustment	Studies, n
Skeletal muscle index(SMI; cm2/m2)	Height	8
Cross-sectional area(CSA; cm2)	None	7
Appendicular skeletal muscle mass (ASMM)-to-height ratio (kg/m2)	Height	1
Psoas:lumbar vertebral index	L4 vertebral body area	1
Thickness, area, volume	None	1

ASMM, appendicular skeletal muscle mass; CSA, cross-sectional area; SMI, skeletal muscle index.

Definition of sarcopenia

The most common method of defining sarcopenia was to establish a threshold intrinsic to the study cohort, as shown in table 4. For example, patients with sarcopenia were those with a CSA below the study population median, or 1 SD from the sex-based mean. Four studies defined sarcopenia as the lowest quartile of the CSA or SMI of the study population. Six studies used a threshold extrinsic to the cohort by using gender-specific reference values for sarcopenia taken from other publications. One study compared measured to estimated CSA to define sarcopenia. Four studies did not explicitly state their cut-off points. Detailed descriptions of the specific cut-off values in the diagnosis of sarcopenia can be found in table 4.

Table 4

Sarcopenia definition

Sarcopenia threshold	Relation	Studies, n
Intrinsic to cohort		10
	Lowest quartile for gender	4
	Below median	2
	Below sex-based mean	1
	5th percentile for gender	1
	<80% of estimated CSA	1
	Below optimal sex-specific cut-off point established by analysis	1
Extrinsic to cohort		4
	SMI<38.5 cm2/m2 in women (<52.4 cm2/m2 in men) 39	2
	ASMM:height ratio <5.46 kg/m220	1
	SMI<4 cm2/m2	1
Not specified		4

ASMM, appendicular skeletal muscle mass; CSA, cross-sectional area; SMI, skeletal muscle index.

Sarcopenia and outcomes

Within the 18 studies, there were five outcomes of interest described: mortality, length of stay, morbidity, in-hospital complications, and independence after discharge (online supplementary digital content 2). Mortality was the most common outcome measured, with 11 studies investigating the association between mortality and sarcopenia. Nine of those studies found that sarcopenia status was correlated to increased patient mortality. There was a wide range of timeframes for mortality measured, with 30-day, 90-day, 6-month, and 1-year mortality all being assessed.

There were six articles that examined the association between length of stay in hospital and sarcopenia, five of which reported a significant correlation between sarcopenia and increased length of stay, and one study which reported no association.

Four articles studied the relationship between morbidity and sarcopenia, all of which suggested a correlation between the sarcopenia status and increased likelihood of various morbidities. Patients with sarcopenia had a higher rate of osteoporotic vertebral fractures,18 low-energy acetabular fractures,19 sustaining a severe thoracic injury from a motor vehicle collision,20 and medical complications such as pneumonia, liver failure, renal failure, and sepsis.17

Two of the four studies which analyzed the relationship between sarcopenia and in-hospital complications found that sarcopenia status was predictive of increased complication rates, whereas the other two studies did not find any relationship. In-hospital complications included adverse events related to respiratory, cardiovascular, infectious, hematological, or renal function.

One study analyzed elderly patient independent living post-traumatic injury and found that sarcopenia status prior to hospital admission was correlated with reduced independence.

As some studies reported multiple outcomes, there were a total of 26 sarcopenia/outcome relationships described within the 18 articles. In total, there were 19 instances of sarcopenia being related to outcome reported with five reporting no correlation. These five reports of no correlation came from three articles, with one article having both correlation and no correlation to outcome reported. For more details, see online supplementary digital content 2.

Discussion

With the exception of two studies which examined muscles of mastication and the study which used DXA imaging modality, there was a majority across studies to define sarcopenia in the acute setting by measuring muscle mass with an axial section of CT imaging at the level of the lumbar spine, with the psoas measured either in isolation or in conjunction with other muscle groups. The anatomic level of the imaging analysis centered around the L3-L4 vertebrae, but there was no clear preference for the exact level. Establishment of a standard anatomic reference site for evaluation of patients for sarcopenia would facilitate future research by removing variation in measurement technique, thereby permitting direct comparison of findings between studies. Based on our findings, we recommend that further investigation into radiographically assessed sarcopenia measure uses CT modalities with caudal end of the L3 vertebrae serving as the anatomic reference point.

SMI was the predominant mode of assessing sarcopenia among the reviewed studies, but there were several variations on this theme to account for morphological features of the patient. Studies like Chang et al21 calculated SMI using lean muscle mass, obtained by setting density thresholds to exclude fatty infiltrate in the imaging software used to calculate CSA. A more holistic approach was taken by Leeper et al, normalizing psoas CSA using a calculated value for body surface area (BSA).6 Akahoshi et al similarly used calculated BSA to generate an estimate for psoas CSA, and defined sarcopenia as a difference between estimate and actual psoas CSA.22

It is clear that muscle CSA alone is not sufficient to define sarcopenia, but exactly how to account for body morphology remains an area for future research. However this is done should be practical for the patient who is acutely ill. The majority of the studies reviewed in this article used height, and as such we recommend that future studies account for patient morphology using patient height. However, Ebbeling et al23 normalized psoas CSA against the CSA of the vertebral body, which has the benefit of being measured accurately and contemporaneously to psoas CSA, rather than a previously recorded height.

The definition of a sarcopenia threshold for nine of the studies was made in relation to the cohort studied, whereas five studies set the sarcopenic threshold using values obtained from other publications. Both intrinsically and extrinsically defined sarcopenic thresholds deserve close scrutiny, while acknowledging that a true reference standard is not possible until normative population data are available.

An intrinsically defined sarcopenia threshold suffers from a reduced ability to generalize findings, as the portion of the study population arbitrarily defined as sarcopenic may not be representative of the wider sarcopenic population. The best example of this is Shibahashi et al,24 where the sarcopenia cut-off value was established using a best fit analysis in which sarcopenic status reflected worse patient outcomes.

By contrast, an extrinsically defined sarcopenia threshold faces scrutiny as to the similarity between the study population and the populations for which those thresholds have been established. Both Deren et al25 and Kaplan et al18 used sarcopenia cut-off values from a 2008 study by Prado et al, which examined sarcopenic obesity in patients with solid tumors of the respiratory and gastrointestinal tract.8 26 27

The majority of the studies reviewed found a correlation between sarcopenia and outcome, despite a wide variability in methods used to measure sarcopenia as well as populations sampled. In total, 16 articles reported the presence of correlation with three reporting no correlation, lending credence to the usefulness of radiographic assessment in predicting the stratification of patient healthcare outcomes. However, clinical adoption of radiographically assessed sarcopenia is predicated on comparison between the patient’s psoas CSA and a normal distribution of psoas CSA which is representative of the population served. Therefore, we recommend further retrospective study using large pools of CT imaging to develop population-specific values for the mean and normal distribution of psoas CSA based on patient demographic factors such as age and sex.

The three studies, by Couch, Ebbeling, and Mccusker, that found no correlation between sarcopenia and measured outcomes had a few shared characteristics. All three studies were retrospective in nature and were performed in Western countries. All three had reasonable sample sizes with 225, 180, and 325, respectively. All three also had a very similar mean age and percentage of male participants, with the mean age of the studies being 76.9, 74 and 76 and the male percentage being 55%, 57%, and 64%. They each used abdominal CT scans to measure the psoas in assessing sarcopenia, although they differed in anatomic references used and muscle characteristics measured.

Couch and Ebbeling both measured the psoas using an axial slice at the L4 inferior aspect of the vertebral body whereas Mccusker measured at the most superior aspect of L3. Couch assessed lean psoas muscle area, Ebbeling measured psoas:lumbar vertebral index, and Mccusker measured total psoas area. In terms of adjustment for body morphology, Couch had none, Ebbeling used L4 vertebral body area and Mccusker used height. Cut-offs for sarcopenia diagnosis varied, with Couch not specifying their criteria, Ebbeling using patients with lower index values compared with cohort median, and Mccusker using the lowest quartile of total psoas CSA. It is not clear if these differences in methodology could account for the shared findings of no correlation between sarcopenia and outcome in these three studies.

There were some limitations to this review. First, most of the studies were performed in Western and English-speaking countries and examined trauma populations, all factors which limit the generalizability of conclusions drawn from such a narrow population. As the purpose of this review was to critically assess radiological measurement of muscle mass as an indicator sarcopenia in the setting of traumatic injury, other methods for diagnosing sarcopenia and non-acute settings were excluded. Furthermore, the results presented would carry more weight were this study conducted as a meta-analysis. However, a meta-analysis was not considered appropriate at this time due to the heterogeneity of method, classifications, and outcomes measured in the published literature.

We also must consider that sarcopenia largely affects the elderly, a population with more comorbidities and, given the opportunistic nature of data collection in the acute care setting, it is not possible to determine if patients included in each study were otherwise healthy prior to the event which resulted in their presentation for medical care. Any unknown or unlisted comorbidities at the time of patient presentation would confound assessment of sarcopenia status as well as outcome, increasing the apparent incidence of sarcopenia in the population studied, while also potentially artificially inflating any relationship between sarcopenia and morbidity or mortality. Finally, there is a bias against publication of research which does not demonstrate a significant relationship between an exposure and an outcome of interest, thus the association between sarcopenia and clinical outcomes may be weaker than the current literature suggests.

As previously noted, radiographic assessment of features like psoas CSA is a surrogate for total muscle mass, which is only one of several elements used in current clinical definitions of sarcopenia, such as the EWGSOP.28 The degree to which radiographic assessments of sarcopenia alone align with clinical definitions has not been clearly established. This is also a direction which we recommend future research focuses on, to clarify the association between clinical and radiographic assessments of sarcopenia.

Of note, the demographic characteristics and outcomes of patients with sarcopenia broadly parallel outcomes seen with the syndrome of frailty, with most frail patients exhibiting some evidence of sarcopenia.29 Although a uniform definition of frailty has yet to emerge, it has come to be recognized as a syndrome broadly characterized by diminished strength, endurance, and reduced physiologic function that thereby increases a person’s vulnerability for developing increased dependency and/or death.30 Although the Trauma-Specific Frailty Index has been used to predict discharge disposition in geriatric patients, it is limited by the requirement of a reliable historian who is able to answer lifestyle questions.30 Thus, in both frailty and sarcopenia, there remains a need for an assessment method for elderly patients who are acutely ill, whose condition may prevent full and accurate assessment using many of the current assessment tools. Radiographic measurements, despite their limitations, offer a first approximation of sarcopenia and the associated syndrome of frailty, and have demonstrated potential to inform admissions and care planning.

Establishing a standardized process for the radiographic assessment of sarcopenia is crucial to any deeper understanding of sarcopenia and its utility as a predictive marker in the clinical space. Further studies to elucidate the ideal measurement process are therefore needed, as it is still unclear which anatomic reference points, muscle characteristics, and body morphology adjustments are most salient. Additionally, there is still a wide variance in the criteria for the acute diagnosis of sarcopenia. Therefore, it would be useful to obtain a normative age and sex-adjusted data curve from a healthy adult population to establish both a uniform diagnostic threshold and methodology for the assessment of sarcopenia.

The majority of the articles analyzed in this review suggested a correlation between sarcopenia and outcomes such as morbidity, mortality, and complications. Taking this relationship into account, assessment of the effects of incorporating radiographic assessment of sarcopenia into patient management plan is needed. Furthermore, a consistent definition of sarcopenia strengthens its applicability to clinical care and ideally contributes to the optimization of hospital resource allocation. Establishing a consistent definition of radiographic sarcopenia also paves the way for future clinical trials to stratify acutely ill populations by degree of sarcopenia, which could increase the predictive capability of this measure, and by extension the strength of recommendations for therapy for these patients.